Cargando…

Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants

SARS-CoV-2 variants have emerged with elevated transmission and a higher risk of infection for vaccinated individuals. We demonstrate that a recombinant prefusion-stabilized spike (rS) protein vaccine based on Beta/B.1.351 (rS-Beta) produces a robust anamnestic response in baboons against SARS-CoV-2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Logue, James, Johnson, Robert M., Patel, Nita, Zhou, Bin, Maciejewski, Sonia, Foreman, Bryant, Zhou, Haixia, Portnoff, Alyse D., Tian, Jing-Hui, Rehman, Asma, McGrath, Marisa E., Haupt, Robert E., Weston, Stuart M., Baracco, Lauren, Hammond, Holly, Guebre-Xabier, Mimi, Dillen, Carly, Madhangi, M., Greene, Ann M., Massare, Michael J., Glenn, Greg M., Smith, Gale, Frieman, Matthew B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972327/ https://www.ncbi.nlm.nih.gov/pubmed/36854666 http://dx.doi.org/10.1038/s41467-022-35606-6

Ejemplares similares

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
por: Guebre-Xabier, Mimi, et al.
Publicado: (2020)

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
por: Tian, Jing-Hui, et al.
Publicado: (2021)

Influenza Hemagglutinin Nanoparticle Vaccine Elicits Broadly Neutralizing Antibodies against Structurally Distinct Domains of H3N2 HA
por: Portnoff, Alyse D., et al.
Publicado: (2020)

Flexible RSV Prefusogenic Fusion Glycoprotein Exposes Multiple Neutralizing Epitopes that May Collectively Contribute to Protective Immunity
por: Patel, Nita, et al.
Publicado: (2020)

Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination
por: Alter, Galit, et al.
Publicado: (2021)

Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M(™) vaccination
por: Gorman, Matthew J, et al.
Publicado: (2021)

Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
por: Gorman, Matthew J., et al.
Publicado: (2021)

SARS-CoV-2 Variant Spike and accessory gene mutations alter pathogenesis
por: McGrath, M.E., et al.
Publicado: (2022)

SARS-CoV-2 variant spike and accessory gene mutations alter pathogenesis
por: McGrath, Marisa E., et al.
Publicado: (2022)

XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants
por: Patel, Nita, et al.
Publicado: (2023)

An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization
por: Raghunandan, Rama, et al.
Publicado: (2014)

Immune Correlates of Protection from Filovirus Efficacy Studies in Non-Human Primates
por: Triplett, Cheryl A., et al.
Publicado: (2022)

Pyronaridine tetraphosphate is an efficacious antiviral and anti-inflammatory active against multiple highly pathogenic coronaviruses
por: Ardanuy, Jeremy, et al.
Publicado: (2023)

Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo
por: Weston, Stuart, et al.
Publicado: (2020)

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial
por: Mallory, Raburn M, et al.
Publicado: (2022)

Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice
por: Haupt, Robert, et al.
Publicado: (2023)

PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19
por: Logue, James, et al.
Publicado: (2022)

Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease
por: Davenport, Bennett J., et al.
Publicado: (2022)

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
por: Keech, Cheryl, et al.
Publicado: (2020)

Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate
por: Bangaru, Sandhya, et al.
Publicado: (2020)

Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate
por: Bangaru, Sandhya, et al.
Publicado: (2020)

mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
por: Nanishi, Etsuro, et al.
Publicado: (2022)

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice
por: Coleman, Christopher M., et al.
Publicado: (2014)

An antidote approach to reduce risk and broaden utility of antibody-based therapeutics
por: Portnoff, Alyse D., et al.
Publicado: (2017)

An engineered genetic selection for ternary protein complexes inspired by a natural three-component hitchhiker mechanism
por: Lee, Hyeon-Cheol, et al.
Publicado: (2014)

2753. Induction of Broadly Cross-Reactive Immune Responses Against A(H3N2) Airuses: Results of a Phase 2 Trial of a Novel Recombinant Hemagglutinin Saponin-Adjuvanted Nanoparticle Seasonal Influenza Vaccine
por: Shinde, Vivek, et al.
Publicado: (2019)

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
por: Dong, Jinhui, et al.
Publicado: (2021)

2’,3’ cyclic-nucleotide 3’-phosphodiesterase (CNP) inhibits SARS-CoV-2 virion assembly by blocking infection-induced mitochondria depolarization
por: Logue, James, et al.
Publicado: (2023)

SIRT-1 is required for release of enveloped enteroviruses
por: Jassey, Alagie, et al.
Publicado: (2023)

Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M–Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine
por: Shinde, Vivek, et al.
Publicado: (2020)

Reduced SARS-CoV-2 mRNA vaccine immunogenicity and protection in mice with diet-induced obesity and insulin resistance
por: O’Meara, Timothy R., et al.
Publicado: (2022)

A Yeast Suppressor Screen Used To Identify Mammalian SIRT1 as a Proviral Factor for Middle East Respiratory Syndrome Coronavirus Replication
por: Weston, Stuart, et al.
Publicado: (2019)

Update on lichen planus and its clinical variants()
por: Weston, Gillian, et al.
Publicado: (2015)

A tRNA Variant Translates Into Seizure Resistance
por: Weston, Matthew C.
Publicado: (2021)

Strong CD4(+) T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination
por: Fries, Louis, et al.
Publicado: (2023)

COVID-19: Knowns, Unknowns, and Questions
por: Weston, Stuart, et al.
Publicado: (2020)

Respiratory Viruses
por: Weston, Stuart, et al.
Publicado: (2019)

Genetic and epigenetic variants in the MTHFR gene are not associated with non-Hodgkin lymphoma
por: Bradshaw, Gabrielle, et al.
Publicado: (2015)

Contextualizing genetic risk score for disease screening and rare variant discovery
por: Zhou, Dan, et al.
Publicado: (2021)

Targeted Sequencing of Alzheimer Disease Genes in African Americans Implicates Novel Risk Variants
por: Logue, Mark W., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gsibsf6eim3mjmk5t7klsk3sas